Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients

Table 4

More than twofold declined or elevated lipid elements of NSCLC patients with adenocarcinoma and squamous carcinoma in pre-RT, RT, or post-RT groups ( or less).

AC/SC pre-RT			AC/SC RT			AC/SC post-RT
Elements	Fold change	value	Elements	Fold change	value	Elements	Fold change	value
PA (16 : 0/22 : 5)	0.334	0.006	PG (18 : 0/22 : 4)	0.339	0.004	PG (18 : 2/20 : 5)	0.367	<0.001
FFA (20 : 5)	0.356	0.034	PI (18 : 0/18 : 3)	0.462	0.013	PA (20 : 0/18 : 3)	0.405	0.009
PA (18 : 2/20 : 2)	0.399	0.002	PA (18 : 1/22 : 4)	0.488	0.028	MAG 20 : 2	0.415	0.049
PG (20 : 0/22 : 4)	0.444	0.018	LPS (16 : 0)	2.383	0.011	PA (16 : 0/20 : 4)	0.415	0.027
PG (20 : 0/20 : 2)	0.451	0.013	MAG 22 : 5	10.759	0.002	PS (16 : 0/16 : 0)	0.429	0.037
PA (18 : 1/22 : 4)	0.457	0.008				PI (16 : 0/22 : 4)	2.528	0.033
PS (20 : 0/20 : 5)	2.416	0.006				PA (16 : 0/16 : 0)	2.625	0.040
PS (18 : 2/20 : 5)	2.845	0.019				PA (14 : 0/20 : 1)	2.687	0.035
						LPA (18 : 1)	3.144	0.044

AC: adenocarcinoma; SC: squamous carcinoma; NSCLC: non-small-cell lung cancer; pre-RT: preradiotherapy; RT: radiotherapy; post-RT: postradiotherapy.